Proposal for CCG-257081 (CCG-257081, Cayman 10009426)

Overview of Therapeutic Candidate:
CCG-257081 is a synthetic small molecule that belongs to the class of MRTF/SRF inhibitors. It was originally discovered through high‐throughput screening efforts aimed at identifying compounds that block RhoA‐induced transcription mediated by the myocardin‐related transcription factor (MRTF) and its cofactor, the serum response factor (SRF). This compound has been chemically optimized from earlier analogues (such as CCG-203971, a close structural relative) to support robust target engagement and favorable pharmacokinetic properties, including ADME profiles that are suitable for in vivo use. As a member of the MRTF/SRF inhibitor family, CCG-257081 falls within a group of agents that have not been traditionally used to treat fibrotic diseases, but rather were originally developed in preclinical settings to dissect the role of the MRTF/SRF axis in transcriptional regulation, cell motility, and extracellular matrix remodeling. In fibrotic contexts, especially in idiopathic pulmonary fibrosis (IPF), the MRTF/SRF pathway drives the transcription of profibrotic genes such as ACTA2—which encodes α-smooth muscle actin (αSMA)—and connective tissue growth factor (CTGF). MRTF/SRF inhibitors have been proposed as a novel means to interrupt this fibrotic transcriptional program, and CCG-257081, in particular, has shown promising biochemical and preclinical antifibrotic data (Ma et al., 2023; Pawelec et al., 2022).

Therapeutic History:
The therapeutic history of compounds targeting the MRTF/SRF transcriptional axis is primarily limited to preclinical investigations, with several studies demonstrating that inhibition of MRTF activity can reduce fibroblast activation and subsequent fibrosis in animal models. For instance, several preclinical studies using bleomycin-induced lung fibrosis models have shown that MRTF/SRF inhibitors such as CCG-203971 reduce fibroblast activation markers, decrease collagen contraction, and lower biochemical markers of fibrosis (Pawelec et al., 2022). In addition, research into myocardin-related transcription factors has demonstrated that genetic depletion or pharmacological inhibition of MRTF-A results in decreased induction of pro-fibrotic genes and mitigates tissue remodeling in models of lung fibrosis (Sisson et al., 2015). While there is no direct record of CCG-257081 having been used clinically for idiopathic pulmonary fibrosis or similar fibrotic diseases, the strong preclinical evidence of MRTF/SRF inhibitors ameliorating fibroblast-driven fibrotic processes in lung models positions it as a promising candidate for repurposing in IPF. Moreover, the favorable ADME profiles reported in these studies further support its potential translational application (Ma et al., 2023; ClinicalTrials.gov, n.d.).

Mechanism of Action:
CCG-257081 acts by inhibiting the activity of the MRTF/SRF transcriptional complex. Under normal physiological conditions, MRTF-A resides in the cytoplasm in complex with monomeric globular actin (G-actin). Upon activation of Rho GTPase signaling pathways and subsequent actin polymerization (formation of filamentous actin, or F-actin), MRTF-A is released from G-actin and translocates into the nucleus. Once in the nucleus, MRTF-A partners with SRF to induce the transcription of genes that are critical for fibroblast activation and myofibroblast differentiation. These target genes include ACTA2 (which encodes αSMA) and CTGF, both of which are central to promoting extracellular matrix production, collagen contraction, and tissue remodeling (Ma et al., 2023; Sisson et al., 2015).
CCG-257081 functions by blocking nuclear translocation of MRTF-A, thereby preventing it from associating with SRF and initiating transcription of its downstream profibrotic targets. Studies have shown that pharmacological agents targeting the MRTF/SRF pathway can reduce mRNA and protein levels of CTGF and αSMA in fibroblasts, ultimately decreasing the contractile ability of these cells as evidenced by reduced 3D collagen gel contraction. In vitro assays have demonstrated that MRTF/SRF inhibitors act at low micromolar concentrations to diminish fibroblast activation, with a clear correlation between target engagement and suppression of the profibrotic gene network (Ma et al., 2023; Pawelec et al., 2022). Additionally, the compound's mechanism is supported by data indicating that inhibition of MRTF nuclear localization translates into measurable biochemical and cellular outcomes, such as lower CTGF expression and reduced collagen contraction in fibroblast cultures (Small, 2012).

Expected Effect:
The hypothesis underlying the use of CCG-257081 in IPF is that by blocking MRTF-A nuclear translocation, the compound will suppress the activation of lung fibroblasts. Specifically, its expected effects in the assay are multi-fold. First, it should reduce nuclear accumulation of MRTF-A in fibroblast foci, particularly in ACTA2+ myofibroblasts, thereby leading to a downregulation of profibrotic gene transcription. This, in turn, should result in decreased expression of key markers such as CTGF and α-smooth muscle actin—a direct indicator of diminished foam fibroblast activation and myofibroblast differentiation (Ma et al., 2023; Sisson et al., 2015). Secondly, in three-dimensional collagen gel contraction assays, treatment with CCG-257081 is expected to lead to a decrease in the contractility of IPF-derived fibroblasts. Such an effect is directly attributable to the reduced transcription of profibrotic genes governing cytoskeletal dynamics and matrix remodeling. Moreover, biochemical studies have shown that treatment with MRTF/SRF inhibitors results in lower mRNA levels of ACTA2 and CTGF, which correlates with a reduction in fibroblast-mediated collagen gel contraction, an important functional readout in assessing antifibrotic efficacy (Ma et al., 2023; Pawelec et al., 2022). The compound must consistently achieve these effects at concentrations that are pharmacologically relevant and non-toxic to lung fibroblasts, thereby demonstrating that its mechanism of action is specific to blocking fibrotic transcription without interfering with cell viability or essential housekeeping functions. This is further supported by data that show selective targeting of fibroblast activation with minimal impact on other cell types such as alveolar epithelial cells or immune cells, ensuring a favorable therapeutic index (Ma et al., 2023).

Overall Evaluation:
Overall, CCG-257081 appears to be a promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis based on several lines of evidence. The key strengths include its mechanistic specificity, as it directly targets the MRTF/SRF transcriptional pathway, which is critically involved in driving the expression of profibrotic genes like CTGF and ACTA2. Preclinical data in bleomycin-induced lung fibrosis models have demonstrated that inhibition of MRTF/SRF signaling can reduce fibroblast activation, collagen gel contraction, and overall fibrotic load, thereby validating the concept that blocking MRTF-A nuclear translocation is a viable strategy against IPF (Ma et al., 2023; Sisson et al., 2015). Additionally, the compound shows efficacy at low micromolar concentrations in vitro, with favorable ADME properties suggesting good pharmacokinetic behavior in vivo (Pawelec et al., 2022).

However, there are notable weaknesses and challenges as well. Although the preclinical models provide strong biochemical and cellular rationale for using MRTF/SRF inhibitors in IPF, clinical data with CCG-257081 are limited or absent. There is a need to establish long-term safety and efficacy in human subjects, as the MRTF/SRF pathway is also involved in homeostatic functions, and off-target effects or systemic toxicity might arise upon prolonged administration. Further, while the suppression of MRTF-mediated transcription is expected to reduce CTGF and αSMA expression, the translation of these effects into meaningful clinical outcomes such as improved lung function and reduced fibrosis progression in IPF patients remains to be validated in clinical trials. In addition, given that approved antifibrotic therapies (pirfenidone and nintedanib) slow rather than reverse disease progression, it is critical to determine whether MRTF/SRF inhibitors can provide additive or superior benefits either as monotherapy or in combination with existing treatments (Ma et al., 2023; Pawelec et al., 2022).

In summary, CCG-257081 exhibits considerable potential as a novel antifibrotic agent for IPF. Its targeted mechanism of action—blocking MRTF-A nuclear translocation and downstream SRF-mediated transcription of key profibrotic genes—addresses a fundamental source of fibroblast activation and extracellular matrix remodeling in the disease. Preclinical studies have demonstrated promising results in terms of reducing myofibroblast activation, collagen contraction, and expression of CTGF and αSMA. While challenges remain in translating these findings to the clinical setting, especially regarding long-term safety and efficacy in human patients, the strong mechanistic rationale and favorable preclinical profile warrant further investigation of CCG-257081 in clinical trials for idiopathic pulmonary fibrosis (Ma et al., 2023; Pawelec et al., 2022; Sisson et al., 2015).

References
ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search: CCG-257081 OR MRTF inhibitor OR myocardin-related transcription factor inhibitor OR serum response factor inhibitor OR CCG-257081 antifibrotic OR CTGF inhibitor AND idiopathic pulmonary fibrosis. Retrieved from https://clinicaltrials.gov

Ma, H.-Y., Vander Heiden, J. A., Uttarwar, S., Xi, Y., N'Diaye, E.-N., LaCanna, R., Caplazi, P., Gierke, S., Moffat, J., Wolters, P. J., & Ding, N. (2023). Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. European Respiratory Journal, 61, 2200604. https://doi.org/10.1183/13993003.00604-2022

Pawelec, K. M., Varnum, M., Harkema, J. R., Auerbach, B., Larsen, S. D., & Neubig, R. R. (2022). Prevention of bleomycin-induced lung fibrosis via inhibition of the MRTF/SRF transcription pathway. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1028

Sisson, T. H., Ajayi, I. O., Subbotina, N., Dodi, A. E., Rodansky, E. S., Chibucos, L. N., Kim, K. K., Keshamouni, V. G., White, E. S., Zhou, Y., Higgins, P. D. R., Larsen, S. D., Neubig, R. R., & Horowitz, J. C. (2015). Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. The American Journal of Pathology, 185(4), 969–986. https://doi.org/10.1016/j.ajpath.2014.12.005

Small, E. M. (2012). The actin–MRTF–SRF gene regulatory axis and myofibroblast differentiation. Journal of Cardiovascular Translational Research, 5(6), 794–804. https://doi.org/10.1007/s12265-012-9397-0
